Dr Carlos Recalde, MD | |
307 4th St, Pleasant Acres, Lewistown, PA 17044-1316 | |
(717) 248-9694 | |
(717) 248-5806 |
Full Name | Dr Carlos Recalde |
---|---|
Gender | Male |
Speciality | Otolaryngology |
Location | 307 4th St, Lewistown, Pennsylvania |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1285779645 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Y00000X | Otolaryngology | MD034182E (Pennsylvania) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Carlos Recalde, MD 307 4th St, Pleasant Acres, Lewistown, PA 17044-1316 Ph: (717) 248-9694 | Dr Carlos Recalde, MD 307 4th St, Pleasant Acres, Lewistown, PA 17044-1316 Ph: (717) 248-9694 |
News Archive
"Parents and officials are going to great lengths to immunize children after militants imposed a ban on polio vaccinations in Pakistan's restive North Waziristan Agency," with some parents "traveling long distances to get their children vaccinated" or "smuggling the vaccine back home," IRIN reports.
Mindray Medical International Limited, a leading developer, manufacturer and marketer of medical devices worldwide, today announced that it will introduce the new DC-8 ultrasound system at the American College of Obstetricians and Gynecologists (ACOG) annual meeting being held in San Diego, May 5-9, 2012.
High levels of alcohol and drug consumption by young people in Europe is leading to an increase in unsafe sexual practices and a consequent rise in sexually-transmitted disease infections, according to a recently published study by the European Institute of Studies on Prevention (IREFREA).
The European Commission has officially announced the selection of the Human Brain Project (HBP) as one of its two FET Flagship projects. The new project will federate European efforts to address one of the greatest challenges of modern science: understanding the human brain.
The U.S. Food and Drug Administration (FDA) approved a label update to include a 200 mg formulation of INTELENCE® (etravirine), a non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated for the treatment of human immunodeficiency virus (HIV-1) in treatment-experienced adults with resistance to an NNRTI and other antiretroviral (ARV) agents.
› Verified 9 days ago